{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["3(2)"],"submitter":["Seethapathy R"],"funding":["Gilead Sciences"],"pubmed_abstract":["<h4>Background</h4>Remdesivir is not currently approved for patients with eGFR <30 ml/min per 1.73 m<sup>2</sup>. We aimed to determine the safety of remdesivir in patients with kidney failure.<h4>Methods</h4>This study was a retrospective cohort study of patients with COVID-19 hospitalized between May 2020 and January 2021 with eGFR <30 ml/min per 1.73 m<sup>2</sup> who received remdesivir and historical controls with COVID-19 hospitalized between March 1, 2020 and April 30, 2020 prior to the emergency use authorization of remdesivir within a large health care system. Patients were 1:1 matched by propensity scores accounting for factors associated with treatment assignment. Adverse events and hospital outcomes were recorded by manual chart review.<h4>Results</h4>The overall cohort include"],"journal":["Kidney360"],"pagination":["269-278"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8967642"],"repository":["biostudies-literature"],"pubmed_title":["A Propensity Score-Matched Observational Study of Remdesivir in Patients with COVID-19 and Severe Kidney Disease."],"pmcid":["PMC8967642"],"pubmed_authors":["Zhao S","Sise ME","Seethapathy R","Strohbehn IA","Long JD"],"additional_accession":[]},"is_claimable":false,"name":"A Propensity Score-Matched Observational Study of Remdesivir in Patients with COVID-19 and Severe Kidney Disease.","description":"<h4>Background</h4>Remdesivir is not currently approved for patients with eGFR <30 ml/min per 1.73 m<sup>2</sup>. We aimed to determine the safety of remdesivir in patients with kidney failure.<h4>Methods</h4>This study was a retrospective cohort study of patients with COVID-19 hospitalized between May 2020 and January 2021 with eGFR <30 ml/min per 1.73 m<sup>2</sup> who received remdesivir and historical controls with COVID-19 hospitalized between March 1, 2020 and April 30, 2020 prior to the emergency use authorization of remdesivir within a large health care system. Patients were 1:1 matched by propensity scores accounting for factors associated with treatment assignment. Adverse events and hospital outcomes were recorded by manual chart review.<h4>Results</h4>The overall cohort include","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-04-04T12:57:49.305Z","creation":"2025-04-04T12:57:49.305Z"},"accession":"S-EPMC8967642","cross_references":{"pubmed":["35373125"],"doi":["10.34067/kid.0006152021","10.34067/KID.0006152021"]}}